Skip to main content

FDA Oncology Update

FDA Oncology Update, FDA Approvals
Rezlidhia New IDH1 Inhibitor FDA Approved for Relapsed or Refractory AML with IDH1 Mutation
Read More
FDA Oncology Update, FDA Approvals
Elahere, First FRα-Directed Antibody, FDA Approved for FRα-Positive, Platinum-Resistant Ovarian Cancer
Read More
FDA Oncology Update, FDA Approvals
Tecvayli, First Bispecific BCMA-Directed CD3 T-Cell Engager, Received FDA Approval for Relapsed or Refractory Multiple Myeloma
Read More
FDA Oncology Update, FDA Approvals
Imjudo, a New CTLA-4 Inhibitor FDA Approved in Combination with Imfinzi for Unresectable Hepatocellular Carcinoma
Read More
FDA Oncology Update, FDA Approvals
Imjudo FDA Approved with Imfinzi and Chemotherapy for Metastatic Non–Small-Cell Lung Cancer
Read More

Results 1 - 5 of 5